FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313589320> ?p ?o ?g. }

• W4313589320 endingPage "11" @default.
• W4313589320 startingPage "1" @default.
• W4313589320 abstract "Amyotrophic lateral sclerosis (ALS) is a neurological disease characterized by the progressive loss of motor neurons in the brain and spinal cord. No effective therapeutic strategies have been established thus far, and therefore there is a significant unmet need for effective therapeutics to arrest the disease and reverse the pathologies induced by it. Although the cause of ALS is not well-defined, it appears to be heterogenous. Currently over 20 genes have been found to be associated with ALS. Family history can only be found in 10&#37; of ALS patients, but in the remaining 90&#37; no association with family history is found. The most common genetic causes are expansion in the <i>C9orf72</i> gene and mutations in <i>superoxide dismutase 1, TDP-43</i>, and <i>FUS</i>. In our recent study, we also found mutations in <i>TDP43</i> and<i> FUS </i>in ALS patients. To understand the pathogenesis of the disease, we set ourselves the task of analyzing the phenotype and function of all key immune effectors in ALS patients, comparing them with either a genetically healthy twin or healthy individuals. Our study demonstrated a significant increase in functional activation of NK and CD8&#43; T cytotoxic immune effectors and release of significant IFN-&gamma; not only by the effector cells but also in the serum of ALS patients. Longitudinal analysis of CD8&#43; T cell-mediated IFN-&gamma; secretion from ALS patients demonstrated continued and sustained increase in IFN-&gamma; secretion with periods of decrease which coincided with certain treatments; however, the effects were largely short-lived. N-acetyl cysteine (NAC), one of the treatments used, is known to block cell death; however, even though such treatment was able to block most of the proinflammatory cytokines, chemokines, and growth factor release, it was not able to block IFN-&gamma; and TNF-&alpha;, the two cytokines we had demonstrated previously to induce differentiation of the cells. In this review, we discuss the contribution of cytotoxic effector cells, especially primary NK cells, supercharged NK cells (sNK), and the contribution of sNK cells in expansion and functional activation of CD8&#43; T cells to memory/effector T cells in the pathogenesis of ALS. Potential new targeted therapeutic strategies are also discussed." @default.
• W4313589320 created "2023-01-06" @default.
• W4313589320 creator A5012870682 @default.
• W4313589320 creator A5035153673 @default.
• W4313589320 creator A5042323006 @default.
• W4313589320 creator A5053449887 @default.
• W4313589320 creator A5061900092 @default.
• W4313589320 creator A5073691565 @default.
• W4313589320 creator A5078452182 @default.
• W4313589320 creator A5080556904 @default.
• W4313589320 date "2023-01-01" @default.
• W4313589320 modified "2023-10-16" @default.
• W4313589320 title "Successes and Challenges in Taming the Beast: Cytotoxic Immune Effectors in Amyotrophic Lateral Sclerosis" @default.
• W4313589320 cites W1492606093 @default.
• W4313589320 cites W1510423530 @default.
• W4313589320 cites W1532988370 @default.
• W4313589320 cites W1604014420 @default.
• W4313589320 cites W1888783223 @default.
• W4313589320 cites W1914000625 @default.
• W4313589320 cites W1969814796 @default.
• W4313589320 cites W1977001219 @default.
• W4313589320 cites W1996873550 @default.
• W4313589320 cites W1996973828 @default.
• W4313589320 cites W2030669661 @default.
• W4313589320 cites W2032333731 @default.
• W4313589320 cites W2038992944 @default.
• W4313589320 cites W2068300781 @default.
• W4313589320 cites W2094821183 @default.
• W4313589320 cites W2100646185 @default.
• W4313589320 cites W2102975924 @default.
• W4313589320 cites W2112506009 @default.
• W4313589320 cites W2119656827 @default.
• W4313589320 cites W2123848058 @default.
• W4313589320 cites W2130116476 @default.
• W4313589320 cites W2140749511 @default.
• W4313589320 cites W2142442655 @default.
• W4313589320 cites W2145697686 @default.
• W4313589320 cites W2146313292 @default.
• W4313589320 cites W2167634911 @default.
• W4313589320 cites W2268886790 @default.
• W4313589320 cites W2592611033 @default.
• W4313589320 cites W2605270876 @default.
• W4313589320 cites W2761403361 @default.
• W4313589320 cites W2782833051 @default.
• W4313589320 cites W2790035192 @default.
• W4313589320 cites W2803371887 @default.
• W4313589320 cites W2911854071 @default.
• W4313589320 cites W3034958546 @default.
• W4313589320 cites W3084494434 @default.
• W4313589320 cites W3108407483 @default.
• W4313589320 cites W4210998205 @default.
• W4313589320 cites W4252979096 @default.
• W4313589320 cites W4308121134 @default.
• W4313589320 doi "https://doi.org/10.1615/critrevimmunol.2023047235" @default.
• W4313589320 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37522557" @default.
• W4313589320 hasPublicationYear "2023" @default.
• W4313589320 type Work @default.
• W4313589320 citedByCount "0" @default.
• W4313589320 crossrefType "journal-article" @default.
• W4313589320 hasAuthorship W4313589320A5012870682 @default.
• W4313589320 hasAuthorship W4313589320A5035153673 @default.
• W4313589320 hasAuthorship W4313589320A5042323006 @default.
• W4313589320 hasAuthorship W4313589320A5053449887 @default.
• W4313589320 hasAuthorship W4313589320A5061900092 @default.
• W4313589320 hasAuthorship W4313589320A5073691565 @default.
• W4313589320 hasAuthorship W4313589320A5078452182 @default.
• W4313589320 hasAuthorship W4313589320A5080556904 @default.
• W4313589320 hasConcept C104317684 @default.
• W4313589320 hasConcept C126322002 @default.
• W4313589320 hasConcept C154317977 @default.
• W4313589320 hasConcept C166252455 @default.
• W4313589320 hasConcept C167672396 @default.
• W4313589320 hasConcept C180754005 @default.
• W4313589320 hasConcept C202751555 @default.
• W4313589320 hasConcept C203014093 @default.
• W4313589320 hasConcept C2777898937 @default.
• W4313589320 hasConcept C2779134260 @default.
• W4313589320 hasConcept C2780596555 @default.
• W4313589320 hasConcept C2780942790 @default.
• W4313589320 hasConcept C51785407 @default.
• W4313589320 hasConcept C54355233 @default.
• W4313589320 hasConcept C71924100 @default.
• W4313589320 hasConcept C86803240 @default.
• W4313589320 hasConcept C8891405 @default.
• W4313589320 hasConceptScore W4313589320C104317684 @default.
• W4313589320 hasConceptScore W4313589320C126322002 @default.
• W4313589320 hasConceptScore W4313589320C154317977 @default.
• W4313589320 hasConceptScore W4313589320C166252455 @default.
• W4313589320 hasConceptScore W4313589320C167672396 @default.
• W4313589320 hasConceptScore W4313589320C180754005 @default.
• W4313589320 hasConceptScore W4313589320C202751555 @default.
• W4313589320 hasConceptScore W4313589320C203014093 @default.
• W4313589320 hasConceptScore W4313589320C2777898937 @default.
• W4313589320 hasConceptScore W4313589320C2779134260 @default.
• W4313589320 hasConceptScore W4313589320C2780596555 @default.
• W4313589320 hasConceptScore W4313589320C2780942790 @default.
• W4313589320 hasConceptScore W4313589320C51785407 @default.
• W4313589320 hasConceptScore W4313589320C54355233 @default.

• next